Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality worldwide. Cardiovascular (CV) risk reduction is important in patients at high risk for a first ...

In the USA Omega-3 market is shifting toward pharma-grade formulations, driven by rising cardiovascular prescriptions. Leading players like KD Pharma, DSM, and BASF are expanding high-purity EPA and ...

The science of VASCEPA, which is underpinned by the REDUCE-IT study and more than 500 additional publications, advancing understanding of the icosapent ethyl clinical benefits and mechanism of ...

DUBLIN and BRIDGEWATER, N.J., March 12, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), today announced financial results for the fourth quarter of 2024 and provided a review of fourth ...

Endoscopic augmentation of the lower oesophageal sphincter using hydrogel implants for the treatment of gastro-oesophageal reflux disease IPG222 27 June 2007 27 June 2007 Carmustine implants and ...

DUBLIN and BRIDGEWATER, N.J., March 12, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), today announced financial results for the fourth quarter of 2024 and provided a review of ...

Amarin Corporation announced the publication of new data in the Journal of the American Heart Association, detailing a post-hoc analysis from the REDUCE-IT study, which found that Icosapent Ethyl ...